Skip to main content
OpenTrials
Completed

NCT Number: NCT02206412

Role of High Mobility Group Box 1 as a Prognostic Biomarker in Patients Undergoing Off-pump Coronary Artery Bypass Graft

High mobility group 1 (HMGB1) protein is both a nuclear factor and a secreted protein, and has recently been identified as a cytokine mediator of systemic inflammation. HMGB1 is released by inflammatory cells actively, or increased during cell death passively and mediates inflammatory response. It has been reported to have association with the prognosis after acute coronary syndrome, ischemia-reperfusion injury of myocardium, atherosclerosis and heart failure. This study aimed to investigate the relationship of serum levels of HMGB1 and post operative prognosis of patients who had undergone off-pump coronary artery bypass graft.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Artery Occlusive Disease

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Anesthesiology & Pain Medicine, Yonsei university college of medicine

Seoul, 120-752, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 20
  • Patients undergoing off-pump coronary artery bypass graft

Exclusion criteria

  • Age < 20
  • Patients undergoing off-pump coronary artery bypass graft with other simultaneous surgery
  • Patients participating other study

Treatment and study plan

Primary outcomes

  1. Maximum value of HMGB1

    Time frame: Change from induction of anesthesia to 2hrs after transfer to intensive care unit

    Measure the maximum value of HMGB1 in all patients and calculate median value. And device into upper median value group and under median value group and compare frequency of composite morbidity/mortality rate between two groups. composite morbidity/mortality is as follows:

    • Stroke
    • Renal failure
    • Prolonged ventilation more than 24 hours
    • Deep sternal wound infection
    • Reoperation for any reason
    • Mortality during the hospitalization for surgery, even if over 30 days

Sponsors and collaborators

Lead sponsor

Yonsei University

Other

Registry information

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Aug 1, 2014
Registry last updated
Jun 21, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.